Helga Droogendijk
Bravis Ziekenhuis(NL)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Biochemical and Molecular Research, Hepatocellular Carcinoma Treatment and Prognosis, Pharmacogenetics and Drug Metabolism, Gastric Cancer Management and Outcomes
Most-Cited Works
- → DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis(2018)408 cited
- → First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group(2023)159 cited
- → Imatinib mesylate in the treatment of systemic mastocytosis(2006)146 cited
- → A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy(2018)89 cited
- → Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis(2023)51 cited
- → Brain Metastases in Patients With Renal Cell Cancer Receiving New Targeted Treatment(2007)42 cited
- → Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch(2015)31 cited
- → First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases(2024)24 cited
- → Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD(2024)11 cited
- → LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group(2023)10 cited